TB-500 (Ac-LKKTETQ) (TB-500)
Thymosin Beta-4 Active Fragment | Healing Peptide
Community Research
Join others researching TB-500 (Ac-LKKTETQ) — share findings, ask questions, and learn from real experiences
TB-500 (Ac-LKKTETQ) is a synthetic derivative of thymosin beta-4 consisting of the N-terminal acetylated 17-23 amino acid fragment. This sequence represents the active site within thymosin beta-4 responsible for actin binding, cell migration, and wound healing. Research shows it promotes endothelial cell differentiation, angiogenesis, keratinocyte migration, collagen deposition, and decreases inflammation. The acetylation protects against N-terminal degradation while maintaining biological activity.
TB-500 contains the LKKTETQ sequence which is the actin-binding motif of full-length thymosin beta-4. This fragment shares many properties of the parent protein regarding cell proliferation, differentiation, and migration. It promotes angiogenesis by upregulating VEGF expression and enhancing endothelial cell sprouting. The peptide undergoes serial cleavage at the C-terminus during metabolism, while the N-terminal acetylation provides protection from degradation.
Molecular Data
Ac
Position 1
Leucine
Position 2
Lysine
Position 3
Position 4
Threonine
Position 5
Glutamic Acid
Position 6
Position 7
Glutamine
Position 8
Research Indications
Promotes dermal wound healing through the active LKKTETQ sequence.
Supports tissue repair comparable to full thymosin beta-4 in research.
Promotes keratinocyte migration and collagen deposition.
Promotes endothelial cell differentiation and new blood vessel formation.
Decreases inflammatory responses in damaged tissues.
Dosing Protocols
TB-500 is typically administered via subcutaneous injection. The N-terminal acetylation provides stability and protection from degradation. Not authorized for medicinal use; research peptide only.
Loading phase
2-2.5 mg
2x weekly for 4-6 weeks
SubQ
Maintenance
2 mg
Weekly or bi-weekly
Reconstitution Instructions
Bacteriostatic water
Insulin syringes
Alcohol swabs
Peptide vial
Sterile work surface
1 Clean work area and hands thoroughly
2 Calculate required BAC water volume
3 Draw BAC water into syringe
4 Inject slowly down vial side
5 Gently swirl until dissolved (never shake)
6 Store reconstituted solution refrigerated
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
Injection site reactions
Mild fatigue
Head rush (reported)
Stop Signs - Discontinue if:
Allergic reactions
Unusual swelling or inflammation
Contraindications
Not authorized for medicinal use
Active cancer (theoretical concern)
Pregnancy or breastfeeding
Prohibited by WADA in sports
Quality Checklist
Good Signs
White lyophilized powder
Clear solution after reconstitution
High purity (>98%)
Intact vacuum seal
Warning Signs
Not authorized for human use
Research chemical only
Bad Signs
Discoloration
Cloudy solution
Particulates visible
Frequently Asked Questions
Is TB-500 fragment (Ac-LKKTETQ) the same as full TB-500?
TB-500 fragment is the active 7-amino-acid sequence (LKKTETQ) of the larger 43-amino-acid thymosin beta-4. Both promote wound healing and cell migration, but the fragment is more stable due to N-terminal acetylation and may be more cost-effective while retaining core regenerative properties.
How quickly does TB-500 fragment accelerate wound healing?
Initial wound healing acceleration appears within 1-7 days, with enhanced cell migration and angiogenesis noticeable by week 1-2. Visible tissue repair improvements typically develop over 2-4 weeks during the loading phase of 2x weekly injections.
Should TB-500 fragment be used with BPC-157 for better healing?
Yes, TB-500 fragment and BPC-157 are commonly combined for synergistic healing. TB-500 promotes cell migration and angiogenesis while BPC-157 upregulates growth factors - together they address multiple healing pathways better than either peptide alone.
Is the N-terminal acetylation in TB-500 fragment necessary for effectiveness?
Yes, the acetylation protects the peptide from degradation at the N-terminus during metabolism while maintaining the active LKKTETQ sequence responsible for wound healing. This modification extends the functional lifespan and improves stability versus non-acetylated versions.
References
TB-500 contains Ac-LKKTETQ, the active site responsible for actin binding and wound healing.
TB-500 is a synthetic version of the active region of thymosin beta-4.
TB-500 undergoes serial cleavage at C-terminus; acetylation protects N-terminus.
Characterized human metabolism of TB-500 using liver microsomes and S9 fraction.
Related Peptides
Commonly combined for enhanced healing effects through different mechanisms.
TB-500 is the active fragment; combining may be redundant.
Both support wound healing and tissue repair through different pathways.
Different mechanisms; may complement for tissue growth.
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.